Síndrome lipodistrofica do HIV VS fatores de risco cardiovascular, consumo alimentar e estado nutricional em pacientes HIV+ em uso de terapia anti-retroviral altamente ativa

Abstract

With the advent of the highly active antiretroviral therapy (HAART), a deep impact was observed in the natural history of the infection for HIV raising the over life of these patients, however taking metabolic alterations as a consequence like dyslipidaemia, insulin resistance, hyperglycemia and redistribution of the physical fat, known as lipodystrophyc syndrome of the HIV (LSHIV). To present a short revision about the LSDHIV, including the medication and the anatomical and biochemical alterations that compose the aim of the LSDHIV, as well as studies that checked the frequency of such alterations in the patients in HAART, in the perspective of contributing to the recognition of this syndrome as an important and current chronic phenomenon. A revision was carried out in the last 13 years with carriers of the LSDHIV, using the key words HIV/AIDS, Lipodystrophyc Syndrome of the HIV, metabolic and morphological alterations of the HIV and the corresponding key words. The literature is forceful in revealing and discussing the anatometabolic alterations present in the HIV patients in use of HAART, standing out highly frequencies of dyslipidaemia, insulin resistance, overweight and abdominal obesity. The LSDHIV represents now an important problem of public health, having in mind the present metabolical and anatomical alterations, important factors of cardiovascular risks, what places theses patients in the condition of group of elevated risk of cardiovascular morbimortality, opening a new perspective in the approach of the AIDS, which must be incorporated inclusive by the public politics of health.